CITATION REPORT List of articles citing

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

DOI: 10.1016/j.jacc.2014.03.021 Journal of the American College of Cardiology, 2014, 64, 2246-2280.

Source: https://exaly.com/paper-pdf/59467106/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
551	Hearts aflutter: Atrial fib guidelines released. 2014 , 20, 16		
550	Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population. 2014 , 39, 600-8		3
549	ClinicianN guide to the updated ABCs of cardiovascular disease prevention. 2014, 3, e001098		17
548	Optimizing selection of antithrombotic therapy in patients requiring PCI and long term anticoagulation. 2014 , 15, 414-20		1
547	Case report: paravalvular leak as a complication of percutaneous catheter ablation for atrial fibrillation. 2014 , 9, 187		8
546	Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. 2014 , 7, 770-7		36
545	Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. 2014 , 30, 1190-5		31
544	Chronic kidney disease and stroke. 2014 , 21, 500-8		28
543	Comparative persistence on Eblockers versus calcium channel blockers for ventricular rate control in nonelderly patients with atrial fibrillation. 2014 , 48, 1570-9		
542	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. 2014 , 3,		33
541	Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. 2014 , 20, 665-72		27
540	Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. 2014 , 11, 1752-9		60
539	Anticoagulation in long-term care: how can we improve medication monitoring?. 2014 , 40, 10-5		1
538	. 2015,		1
537	Hybrid approach to treatment of atrial fibrillation. 2015 , 1, 19-24		1
536	MRI definition of atrial substrate. 2015 , 101-108		
535	The prognostic effects of ventricular heart rate among patients with permanent atrial fibrillation with and without coronary artery disease: a multicenter prospective observational study. 2015 , 94, e92	20	5

(2015-2015)

534	Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ? 2. 2015 , 3, 2050312115613350		10
533	Rapid automatic segmentation of abnormal tissue in late gadolinium enhancement cardiovascular magnetic resonance images for improved management of long-standing persistent atrial fibrillation. 2015 , 14, 88		9
532	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. 2015 , 13, 29		1
531	Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?. 2015 , 19 Suppl 3, S40-50		1
530	The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?. 2015 , 66, 530-9		1
529	Percutaneous closure of the left atrial appendage for stroke prevention in atrial fibrillation: an alternative to lifelong anticoagulation?. 2015 , 38, 371-84		1
528	Nonvitamin K antagonist oral anticoagulants in everyday practice: Stroke prevention in atrial fibrillation and treatment of venous thromboembolism. 2015 , 27, 721-31		2
527	Triple therapy for atrial fibrillation and percutaneous coronary intervention. 2015 , 30, 690-6		1
526	Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?. 2015 , 8, 217-28		11
525	Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation. 2015 , 21, 1054-62		28
524	Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. 2015, 4, 44-6		2
523	Prospectively quantifying the propensity for atrial fibrillation: a mechanistic formulation. <i>PLoS ONE</i> , 2015 , 10, e0118746	3.7	3
522	Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease. <i>PLoS ONE</i> , 2015 , 10, e0131479	3.7	2
521	Developing a New Computer-Aided Clinical Decision Support System for Prediction of Successful Postcardioversion Patients with Persistent Atrial Fibrillation. 2015 , 2015, 527815		2
520	Preventing medication errors in transitions of care: A patient case approach. 2015 , 21, 79-90		2
519	Diltiazem?. 2015,		1
518	Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?. 2015 , 17, 1514-7		13
517	Management of postoperative atrial fibrillation in cardiac surgery patients. 2015 , 19, 122-9		15

Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial. **2015**, 11, 147-51

515	Emergency Department Management of Atrial Fibrillation and Flutter and Patient Quality of Life at One Month Postvisit. 2015 , 66, 646-654.e2	14
514	Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. 2015 , 12, 1192-200	9
513	Empirical mode decomposition of multiple ECG leads for catheter ablation long-term outcome prediction in persistent atrial fibrillation. 2015 , 2015, 105-8	
512	Perioperative management of anticoagulants and antiplatelet agents in oculoplastic surgery. 2015 , 26, 422-8	12
511	Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. 2015 , 170, 1234-42	3
510	Left atrial appendage closure for stroke prevention in atrial fibrillation: response to an unmet need with an unclear direction. 2015 , 8, 8-10	1
509	Monitoring and management of patients with chronic atrial fibrillation: Is there added value in the identification of clinical phenotypes?. 2015 , 14, 382-3	
508	Empirical mode decomposition for noninvasive atrial fibrillation dominant frequency estimation. 2015 ,	
507	Preventing medication errors in transitions of care: A patient case approach. 2015 , 55, e264-74; quiz e275-6	25
506	Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. 2015 , 43, 172-9	12
505	microRNA expression changes after atrial fibrillation catheter ablation. 2015 , 16, 1863-77	32
504	Catheter Ablation of Cardiac Arrhythmias. 2015 , 493-520	
503	Antithrombotic management of atrial fibrillation in the elderly. 2015 , 99, 417-30	9
502	Update in cardiac arrhythmias and pacing. 2015 , 68, 226-33	
501	Data strengthen to support recommending anticoagulant therapy for all atrial fibrillation patients with a CHA2DS2-VASc score â¶. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 643-4	4
500	Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy. 2015 , 44, 141-9	9
499	Colchicine for postoperative atrial fibrillation prevention: is its efficacy questionable?. 2015 , 35, 239-40	2

(2015-2015)

4:	98	Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation. 2015 , 43, 161-7	17	
4:	97	Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. 2015 , 37, 53-9	25	
4:	96	Temas de actualidad en arritmias y estimulaciñ cardiaca. 2015 , 68, 226-233	4	
4:	95	Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study. 2015 , 19, 849-56	30	
4:	94	HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. 2015 , 12, e69-100	299	
4:	93	Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. 2015 , 41, 146-53	14	
4:	92	Left atrial appendage occlusion for stroke prevention. 2015 , 40, 429-76	6	
4:	91	Risk and prediction of dementia in patients with atrial fibrillationa nationwide population-based cohort study. 2015 , 199, 25-30	63	
4:	90	Triple TherapyCan We Replace More With Better?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 628-30	0	
4	89	Atrial fibrillation and heart failure: update 2015. 2015 , 58, 126-35	36	
4	88	Using photoplethysmography in heart rate monitoring of patients with epilepsy. 2015 , 45, 142-5	25	
4	87	Evolution of the American College of Cardiology/American Heart Association Clinical Guidelines. Journal of the American College of Cardiology, 2015 , 65, 2726-34	17	
4	86	Digoxin: In the Cross Hairs Again. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2699-701 15.1	3	
4	85	Team-Based Care for Managing Cardiac Comorbidities in Heart Failure. 2015 , 11, 407-17	6	
4	84	Defining non-valvular atrial fibrillation while selecting anticoagulation therapy. 2015, 76, 66-7		
4	83	Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?. 2015 , 41, 195-207	15	
4	82	Identification of dabigatran etexilate major degradation pathways by liquid chromatography coupled to multi stage high-resolution mass spectrometry. 2015 , 5, 45068-45081	8	
4	81	Atrial and ventricular arrhythmias in hypertrophic cardiomyopathy. 2015 , 7, 173-86	19	

480	Reduction of Radiation Exposure in Atrial Fibrillation Ablation Using a New Image Integration Module: A Prospective Randomized Trial in Patients Undergoing Pulmonary Vein Isolation. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 747-53	2.7	12
479	Misconceptions and Facts About Atrial Fibrillation. 2015 , 128, 938-42		8
478	Practical management of anticoagulation in patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1340-1360	15.1	67
477	The role of left atrial imaging in the management of atrial fibrillation. 2015 , 58, 136-51		16
476	Analysis of enoxaparin dose titration at a large, tertiary teaching facility. 2015, 21, 720-3		
475	Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1339-47	15.1	92
474	Characterization of pleural effusion after left atrial appendage exclusion using the Lariat procedure. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 515-9	2.7	3
473	Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. 2015 , 38, 490-8		13
472	Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation. 2015 , 58, 168-76		5
471	Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. 2015 , 31, 1831-40		21
470	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. 2015 , 46, 2830-7		5
469	Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. 2015 , 4,		21
468	Heart Failure and Atrial Fibrillation. 2015 , 27, 427-38		
467	Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. 2015 , 16, 1103.e1-19		29
466	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. 2015 , 181, 247-54		5
465	Ablation of atrial fibrillation. 2015 , 25, 409-19		8
464	Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey. 2016 , 22, 147-52		6
463	Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients. 2016 , 129, 2143-8		1

462	Attempting to cure atrial fibrillation during mitral valve surgery: can we measure a benefit?. 2016 , 2, 235-236		
461	Functional Role and Mechanism of microRNA-28b in Atrial Myocyte in a Persistent Atrial Fibrillation Rat Model. 2016 , 22, 3073-8		4
460	INR Stability, Clinical Importance, and Predictors in Patients With Atrial Fibrillation and Venous Thromboembolism Receiving Vitamin K Antagonists. 2016 , 32, 253-259		78
459	Utilization and Predictors of Electrical Cardioversion in Patients Hospitalized for Atrial Fibrillation. 2016 , 2016, 8956020		9
458	Direct Oral Anticoagulants in Emergency Trauma Admissions. 2016 , 113, 575-82		20
457	Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2016 , 11, e0147245	3.7	20
456	Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. <i>PLoS ONE</i> , 2016 , 11, e0148914	3.7	16
455	Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review. 2016 , 36, 230-6		14
454	Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Meta-Analysis. 2016 , 95, e2741		20
453	Efficacy of Cryoballoon Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016 , 27, 423-7	2.7	29
452	Using new non-invasive quick method to detect Borrelia Burgdorferi (B.B.) infection from specific parts of the heart in "seemingly normal" ECGs, and from the ECGs of Atrial Fibrillation (AF), a majority of AF ECGs are found to have: 1) Significant B.B. infection, 2) Markedly increased ANP, 3) Increased Cardiac Troponin I & 4) Markedly reduced Taurine. These 4 factors were mainly localized		
451	OCT imaging of myocardium extending to pulmonary veins at the L-atrium. 2015 , 40, 297-333		
450	Impact of B-type natriuretic peptide (BNP) on development of atrial fibrillation in people with Type 2 diabetes. 2016 , 33, 1118-24		4
449	Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. 2016 , 37, 3515-3522		218
448	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2016 , 27, 804-10	2.7	27
447	Stroke Prevention in Atrial Fibrillation: Current Strategies and Recommendations. 2016, 1, 157-164		
446	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After PCI. 2016 , 443-452		
445	What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. 2016 , 18, I18-I24		2

11

Uso de antiarrÉmicos en el tratamiento de la fibrilacifi auricular. Estrategia de control del ritmo. 444 **2016**, 23, 112-117 Towards real-time MRI-guided 3D localization of deforming targets for non-invasive cardiac 13 radiosurgery. 2016, 61, 7848-7863 Escalas de evaluacifi del riesgo tromboemblico y hemorrgico en la fibrilacifi auricular. Revista 442 0.2 Espanola De Cardiologia Suplementos, **2016**, 16, 25-32 Generalidades de la fibrilaciñ auricular. 2016, 23, 5-8 441 Crioablacifi con balfi en fibrilacifi auricular. 2016, 23, 138-142 440 Navegacifi remota en la fibrilacifi auricular. 2016, 23, 151-158 439 Tratamiento farmacolgico de la fibrilacin auricular. Antiarremicos y anticoagulantes orales. 438 0.2 Revista Espanola De Cardiologia Suplementos, **2016**, 16, 33-39 The clinical dilemma of heart failure with preserved ejection fraction: an update on 5 437 pathophysiology and management for physicians. 2016, 92, 346-55 Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias. 8 436 2016, 8, 423-36 A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized 435 trial. 2016, 54, 157-164 Innovative pacing: Recent advances, emerging technologies, and future directions in cardiac pacing. 2 434 2016, 26, 452-63 Atrial Fibrillation in Patients With Left Ventricular Assist Devices: Incidence, Predictors, and Clinical 20 433 Outcomes. 2016, 2, 793-798 Early Postoperative Care After CABG. 2016, 75-97 432 The Risk of Hospital Admission Due to Traumatic Brain Injury Is încreased in Older Persons With 431 9 Severe Functional Limitations. 2016, 17, 609-12 Left atrial thrombi and spontaneous echo contrast in patients with atrial fibrillation: Systematic 9 430 analysis of a single-center experience. 2016, 41, 706-714 Contact force sensing during atrial fibrillation ablation: clinical experience and effects on 6 429 outcomes. **2016**, 14, 749-59 Quality Evaluation in Non-Invasive Cardiovascular Imaging. 2016, 428 1

Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. 2016, 73, 563-7

426	Influence of Renal Insufficiency on the Prescription of Evidence-Based Medicines in Patients With Coronary Artery Disease and Its Prognostic Significance: A Retrospective Cohort Study. 2016 , 95, e2740		3
425	Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. 2016 , 194, 1319-1336		115
424	New Role of Biomarkers in Atrial Fibrillation. 2016 , 507-539		
423	Effectiveness and Safety of an Independently Run Nurse Practitioner Outpatient Cardioversion Program (2009 to 2014). 2016 , 118, 1842-1846		7
422	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. 2016 , 39, 739-746		10
421	Impact of CHADSVASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multi-payer Analysis. 2016 , 38, 2196-2203.e5		2
420	Direct Oral Anticoagulants: A Patient-centered Review. 2016 , 12, 523-529		
419	Cost Effectiveness of Implantable Cardiac Monitor-Guided Intermittent Anticoagulation for Atrial Fibrillation: An Analysis of the REACT.COM Pilot Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2016 , 27, 1304-1311	2.7	8
418	Gastrointestinal complications associated with catheter ablation for atrial fibrillation. 2016, 224, 424-43	0	25
417	Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. 2016 , 18, 65		6
416	Risk Stratification in Atrial Fibrillation and Observation Unit Entry. Contemporary Cardiology, 2016, 125-1	13.1	
415	Association of Left Atrial Function Index With Late Atrial Fibrillation Recurrence after Catheter Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2016 , 27, 1411-1419		
	Ablacion. Journal of Caralovascalar Electrophysiology, 2010, 21, 1411-1417	2.7	10
414	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 2016 , 182, 28-35	2.7	7
414	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and	2.7	
	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 2016 , 182, 28-35	2.7	7
413	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 2016, 182, 28-35 Gender Differences in Clinical Outcomes after Catheter Ablation of Atrial Fibrillation. 2016, 2, 703-710 Prognostic Implications of Left Ventricular Scar Determined by Late Gadolinium Enhanced Cardiac Magnetic Resonance in Patients With Atrial Fibrillation. 2016, 118, 991-7	0.1	7
413	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 2016, 182, 28-35 Gender Differences in Clinical Outcomes after Catheter Ablation of Atrial Fibrillation. 2016, 2, 703-710 Prognostic Implications of Left Ventricular Scar Determined by Late Gadolinium Enhanced Cardiac Magnetic Resonance in Patients With Atrial Fibrillation. 2016, 118, 991-7 Rate Control in Atrial Fibrillation. Contemporary Cardiology, 2016, 67-77		7

408	Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study: The VERSATILE Study in Atrial Fibrillation Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2016 , 27 Suppl 1, S17-22	2.7	5
407	Gerontechnologies for Older Patients with Heart Failure: What is the Role of Smartphones, Tablets, and Remote Monitoring Devices in Improving Symptom Monitoring and Self-Care Management?. 2016 , 10, 1		17
406	International normalised ratio stability in patients aged 80 years and over taking warfarin for non-valvular atrial fibrillation. 2016 , 7, 411-415		
405	Atrial Fibrillation Research in the Observation Unit and the Emergency Department. <i>Contemporary Cardiology</i> , 2016 , 239-247	0.1	
404	Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services. 2016 , 46, 1166-1171		1
403	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. 2016 , 5,		14
402	Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis. 2016 , 80, 860-9		64
401	The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure. 2016 , 224, 431-436		3
400	Non-invasive prediction of catheter ablation outcome in persistent atrial fibrillation by fibrillatory wave amplitude computation in multiple electrocardiogram leads. 2016 , 109, 679-688		9
399	Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation. 2016 , 41, 667-676		10
398	Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. 2017 , 38, 1285-1293		63
397	Mechanistically based mapping of human cardiac fibrillation. 2016 , 594, 2399-415		28
396	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2217-2228	15.1	157
395	Utilidad de la automonitorizaciñ en el tratamiento de la terapia con warfarina. 2016 , 23, 78-81		
394	Patient-centered treatment in atrial fibrillation. 2016 , 29, 1-4		
393	Principles of Arrhythmia Management During Pregnancy. 2016 , 1, 143-155		
392	Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation. 2016, 46, 792-7		16
391	Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice. 2016 , 41, 432-40		3

(2016-2016)

390	Carotid Intima-Media Thickness and Arterial Stiffness and the Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. 2016 , 5,		51	
389	Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2913-23	15.1	95	
388	The role of catheter ablation in the management of atrial fibrillation. 2016, 16, 267-71		2	
387	A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. 2016 , 178, 45-54		42	
386	Dyspnea and Hemoptysis. 2016 , 12, e333-e336			
385	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. 2016 , 14, 14		27	
384	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2888-99	15.1	117	
383	Use of delayed-enhancement magnetic resonance imaging for fibrosis detection in the atria: a review. 2017 , 19, 180-189		45	
382	Genetics of atrial fibrillation: from families to genomes. 2016 , 61, 61-70		49	
381	Device-identified atrial fibrillation at pacing clinics. Should it guide anticoagulation?. 2016 , 207, 378-81		6	
380	Atrial Flutter and Fibrillation in the Emergency Setting. 2016, 61-87			
379	Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. 2016 , 2, 221-229		22	
378	Efficacy and safety of catheter ablation vs. rate control of atrial fibrillation in systolic left ventricular dysfunction: A meta-analysis and systematic review. 2016 , 41, 342-50		9	
377	Emerging Tools for Stroke Prevention in Atrial Fibrillation. 2016 , 4, 26-39		9	
376	Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. 2016 , 32, 1201-7		20	
375	Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non-frail?. 2016 , 46, 86-95		26	
374	A case report of the new PolyzeneâEF COBRA PzFâ[Nanocoated Coronary Stent System (NCS): Addressing an unmet clinical need. 2016 , 17, 209-11		8	
373	The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. 2016 , 14, 177-87		15	

372	Recalibration of the HAS-BLED Score: Should Hemorrhagic Stroke Account for One or Two Points?. 2016 , 149, 311-314	9
371	Delayed Pulmonary Artery Perforation With Left Atrial Appendage Occluder Hooks. 2016 , 101, e37-9	11
370	Management of antithrombotic therapy during cardiac implantable device surgery. 2016, 32, 163-9	12
369	Effects of inspiratory muscle training on pulmonary function, respiratory muscle strength and functional capacity in patients with atrial fibrillation: a randomized controlled trial. 2016 , 30, 1165-1174	18
368	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. 2016 , 16, 221-35	16
367	Effect of Frailty and Age on Platelet Aggregation and Response to Aspirin in Older Patients with Atrial Fibrillation: A Pilot Study. 2016 , 5, 51-62	11
366	External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study. 2016 , 18, 1265-72	47
365	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. 2016 , 18, 973-8	16
364	Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. 2016 , 133, 1540-7	83
363	The Arrhythmic Patient in the Emergency Department. 2016,	
362	[Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia: Case report of an 89-year-old woman]. 2016 , 111, 458-62	2
361	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2016 , 13, e92-135	16
360	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the</i>	66
359	American College of Cardiology, 2016 , 67, 1575-1623 Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians?. 2016 , 13, 46-53	53
358	Prevalencia de fibrilaciñ auricular y caracterßticas de la fibrilaciñ auricular no valvular en la poblaciñ general. Registro AFINVA. 2017 , 24, 26-33	4
357	Role of Digoxin in Atrial Fibrillation. 2017 , 30, 434-440	13
356	Multi-morbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs. Outcomes of the AFASTER study. 2017 , 16, 113-124	18
355	Pulmonary vein potential mapping in atrial fibrillation with high density and standard spiral (lasso) catheters: A comparative study. 2017 , 33, 192-200	6

354	[Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study]. 2017, 43, 477-485	10
353	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. 2017 , 38, 888-896	29
352	A Cautionary Tone Before Expanded Adoption of the Proposed CHADS-VASc R Score. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 251	1
351	Characteristics of Anatomy and Function of the Left Atrial Appendage and Their Relationships in Patients with Cardioembolic Stroke: A 3-Dimensional Transesophageal Echocardiography Study. 2017 , 26, 470-479	20
350	Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention. 2017 , 39, 173-180	9
349	Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation-a Microsimulation Analysis. 2017 , 32, 464-470	4
348	Atrial Fibrillation. 2017 , 258-277	
347	PatientsNand PhysiciansNPerceptions Regarding the Benefits of Atrial Fibrillation Ablation. 2017 , 40, 362-371	8
346	The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: A randomized controlled clinical trial. 2017 , 38, 111-116	13
345	The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective. 2017 , 20, 599-605	3
344	Personalized, assessment-based, and tiered medical education curriculum integrating treatment guidelines for atrial fibrillation. 2017 , 40, 455-460	4
343	Recurrent Post-Ablation Paroxysmal Atrial Fibrillation Shares Substrates With Persistent Atrial Fibrillation : An 11-Center Study. 2017 , 3, 393-402	12
342	The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study. 2017 , 29, 1129-1138	13
341	Clinical Benefit of Ablating Localized Sources for Human Atrial Fibrillation: The Indiana University FIRM Registry. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1247-1256	83
340	Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. 2017 , 15, 835-847	130
339	High-Sensitivity Troponin as a Biomarker in Heart Rhythm Disease. 2017 , 119, 1407-1413	19
338	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. 2017 , 49, 946-952	176
337	Evaluating Gaussian and Rayleigh-Based Mathematical Models for T and P-waves in ECG. 2017 , 15, 843-853	8

336	Cardiovascular Outcomes With Surgical Left Atrial Appendage Exclusion in Patients With Atrial Fibrillation Who Underwent Valvular Heart Surgery (from the National Inpatient Sample Database). 2017 , 119, 2056-2060	30
335	Guidelines on the management of atrial fibrillation in the emergency department: a critical appraisal. 2017 , 12, 693-703	10
334	Intra-Atrial Conduction Delay Revealed by Multisite Incremental Atrial Pacing is an Independent Marker of Remodeling in Human Atrial Fibrillation. 2017 , 3, 1006-1017	14
333	Pathway for the Management of Atrial Fibrillation and Atrial Flutter. <i>Critical Pathways in Cardiology</i> , 2017 , 16, 47-52	3
332	Evaluation of the effect of torsemide on warfarin dosage requirements. 2017 , 39, 831-835	2
331	Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study. 2017 , 6, 261-271	
330	Oral Anticoagulation Therapy. 2017 ,	1
329	Examining the impact of active clearance of chest drainage catheters on postoperative atrial fibrillation. 2017 , 154, 501-508	15
328	Importance of balancing follow-up time and impact of oral-anticoagulant usersNelection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. 2017 , 33, 1033-1043	6
327	Analysis of the Association Between Electrocardiographic P-wave Characteristics and Atrial Fibrillation in the REGICOR Study. 2017 , 70, 841-847	5
326	Cardiac Management in the Frail Elderly Patient and the Oldest Old. 2017,	1
325	Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease. 2017 , 51, 445-450	44
324	Effect of Atrial Fibrillation on Contrast-Induced Nephropathy Development in Patients With Non-ST-Segment Elevation Myocardial Infarction. 2017 , 68, 871-876	4
323	Clinical implication of frailty assessment in older patients with atrial fibrillation. 2017, 70, 1-7	22
322	Evaluaciñ de costo-efectividad de los nuevos anticoagulantes orales en pacientes con fibrilaciñ auricular no valvular. 2017 , 24, 87-95	1
321	Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. 2017 , 33, 631-638	
320	Modeling of the photoplethysmogram during atrial fibrillation. 2017 , 81, 130-138	35
319	New oral anticoagulants in patients with chronic kidney disease. 2017 , 37, 244-252	9

(2017-2017)

318	Catheter Ablation for Atrial Fibrillation in Patients With Watchman Left Atrial Appendage Occlusion Device: Results from a Multicenter Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2017 , 28, 139-146	2.7	22
317	Immediate impact of positive airway pressure on atrial fibrillation. 2017 , 39, 84-86		
316	Atrial ectopy as a mediator of the association between race and atrial fibrillation. 2017, 14, 1856-1861		5
315	Anatomical and electrical remodeling with incomplete left atrial appendage ligation: Results from the LAALA-AF registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2017 , 28, 1433-1442	2.7	8
314	Impact of race and gender on clinical outcomes of catheter ablation in patients with atrial fibrillation. 2017 , 40, 1073-1079		7
313	Atrial Fibrillation in Athletes: A Lesson in the Virtue of Moderation. 2017 , 3, 921-928		23
312	Cardiac Arrhythmias. 2017 , 2, 589-602		
311	Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. 2017 , 71, e12974		2
310	Asociacifi entre las caracterfiticas de la onda P y la fibrilacifi auricular en el estudio REGICOR. 2017 , 70, 841-847		15
309	New oral anticoagulants in patients with chronic kidney disease. 2017 , 37, 244-252		5
308	Prophylactic Amidarone Treatment for Atrial Fibrillation After Coronary Artery Bypass Surgery. 2017 , 13, 433-440		2
307	Pharmacological stroke prevention in the elderly with atrial fibrillation in Poland - Results of PolSenior study. 2017 , 51, 382-387		О
306	Fibrillation atriale postopfatoire : un vhement föheux 1. 2017 , 21, 77-84		
305	Atrial Cardiomyopathy: A Useful Notion in Cardiac Disease Management or a Passing Fad?. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 756-765	15.1	90
304	Predictive role of CHADS-VASc score for cardiovascular events and death in patients with arterial hypertension and stable sinus rhythm. 2017 , 24, 1584-1593		15
303	Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. 2017 , 29, 551-561		4
302	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. 2017 , 7, 207-217		12
301	Anticoagulant options in atrial fibrillation: When new treatments become standard practice. 2017 , 42, 29-35		

300	A Multicenter Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis. 2017 , 51, 954-960	16
299	Outcomes Associated With Electrical Cardioversion for Atrial Fibrillation When Performed Autonomously by an Advanced Practice Provider. 2017 , 3, 1447-1452	5
298	Exclusion of the left atrial appendage: an effective method. 2017, 33, 110-116	
297	Single-lead f-wave extraction using diffusion geometry. 2017 , 38, 1310-1334	11
296	Kriterien fildie Notwendigkeit und Dauer von Krankenhausbehandlung bei elektiven rhythmologischen Eingriffen. 2017 , 11, 209-218	2
295	Impact of Left Atrial Appendage Exclusion on Cardiovascular Outcomes in Patients With Atrial Fibrillation Undergoing Coronary Artery Bypass Grafting (From the National Inpatient Sample Database). 2017 , 120, 953-958	14
294	Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. 2017 , 16, 75	20
293	Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. 2017 , 227, 808-812	15
292	The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. 2017 , 10, 5-15	3
291	Diagnosis, pathophysiology, and management of exercise-induced arrhythmias. 2017 , 14, 88-101	54
290	The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective. 2017 , 20, 266-272	4
289	Atrial arrhythmia after transcatheter closure of secundum atrial septal defects in patients â日0 years of age. 2017 , 19, 1322-1326	13
288	Flecainide Toxicity: A Case Report and Systematic Review of its Electrocardiographic Patterns and Management. 2017 , 17, 260-266	25
287	Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective. 2017 , 15, 363-374	1
286	A Randomised Controlled Trial on the Effect of Nurse-Led Educational Intervention at the Time of Catheter Ablation for Atrial Fibrillation on Quality of Life, Symptom Severity and Rehospitalisation. 2017 , 26, 73-81	17
285	Factors Affecting PatientsNPerception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants. 2017 , 10, 163-185	25
284	Mild troponin elevation in patients admitted to the emergency department with atrial fibrillation: 30-day post-discharge prognostic significance. 2018 , 13, 333-341	3
283	The Sexually Dimorphic Characteristics of the Pathophysiology and Treatment of Atrial Fibrillation. 2017 , 381-390	

282 Introductory Chapter: Embolic Diseases - Unusual Therapies and Challenges. 2017,

281	Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation. 2017 , 117, 761-771	4
280	Postoperative Atrial Fibrillation Prophylaxis and Lung Resection âl Dur Experience with 608 Consecutive Patients. 2017 , 56, 64-72	1
279	Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. <i>Frontiers in Cardiovascular Medicine</i> , 2017 , 4, 42	1
278	Ten-year outcome of intraoperative treatment of atrial fibrillation using radiofrequency ablation. 2017 , 13, 1233-1237	1
277	Left Atrial Appendage Closure: Is the Strategy Enough to Lower Long-Term Stroke Risk?. 2017 , 11, 1	
276	Ablation of Focal Impulses and Rotational Sources: What Can Be Learned from Differing Procedural Outcomes?. 2017 , 11, 1	9
275	Do All Patients with Atrial Fibrillation Need Long-Term Anticoagulation?. 2017 , 7, 955	1
274	Clinical Stroke prevention in atrial fibrillation. 2017 , 47, 13-23	2
273	Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. 2017 , 47, 644-662	26
272	Pharmacologic Rhythm Control versus Rate Control in Heart Failure and Atrial Fibrillation. 2017, 4,	
271	Utilidad del dplex transcraneal en la Neurologa: serie de casos	
270	The absence of effect of ganglionated plexi ablation on heart rate variability parameters in patients after thoracoscopic ablation for atrial fibrillation. 2017 , 9, 4997-5007	1
269	Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey. 2018 , 72, e13072	13
268	2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations. 2018 , 7,	19
267	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2018 , 39, 2314-2325	104
266	Risks and outcomes of direct current cardioversion in children and young adults with congenital heart disease. 2018 , 41, 472-479	2
265	Fully automatic segmentation and objective assessment of atrial scars for long-standing persistent atrial fibrillation patients using late gadolinium-enhanced MRI. 2018 , 45, 1562-1576	32

264	Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. 2018 , 84, 1544-1556	11
263	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. 2018 , 200, 102-109	5
262	Age modifies the risk of atrial fibrillation among athletes: A systematic literature review and meta-analysis. 2018 , 18, 25-29	11
261	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1063-1074	99
260	Anticoagulation in the Patient with Cancer. 2018, 425-440	1
259	Circulating miRNAs in acute new-onset atrial fibrillation and their target mRNA network. <i>Journal of Cardiovascular Electrophysiology</i> , 2018 , 29, 1159-1166	21
258	Current State of Left Atrial Appendage Closure. 2018 , 20, 42	7
257	Stroke prevention in atrial fibrillation: re-defining Meal-world dataNwithin the broader data universe. 2018 , 39, 2932-2941	19
256	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. 2018 , 7,	5
255	Temporal trends in safety and complication rates of catheter ablation for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018 , 29, 854-860	36
254	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. 2018 , 28, 469-480	O
253	Novel oral anticoagulant use in adult Fontan patients: A single center experience. 2018 , 13, 541-547	26
252	[Quality of care and safety indicators in anticoagulated patients with non-valvular auricular fibrillation and deep venous thromboembolic disease]. 2018 , 33, 68-74	1
251	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. 2018 , 39, 1726-1735a	112
250	Remote Monitoring for Chronic Disease Management: Atrial Fibrillation and Heart Failure. 2018 , 10, 43-58	2
249	Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation. 2018 , 60, 542-549	5
248	Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran. 2018 , 75, 177-182	3
247	Cryptogenic acute limb ischemia: a retrospective cohort study defining a previously undescribed clinical entity. 2018 , 45, 397-402	2

246	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. 2018 , 60, 514-523	7
245	Impact of anticoagulation and platelet antiaggregation on anaemia and haemorragic events in patients with chronic kidney disease stages 3 and 4. 2018 , 151, 476-480	
244	Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation. 2018, 20, 32	16
243	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Where Are We Now?. 2018 , 52, 884-897	1
242	Novel oral anticoagulants in chronic kidney disease: ready for prime time?. 2018 , 27, 201-208	4
241	Ablation Outcomes and Predictors of Mortality Following Catheter Ablation for Ventricular Tachycardia: Data From the German Multicenter Ablation Registry. 2018 , 7,	8
240	Chronic Medications and Maxillofacial Surgery. 2018 , 161-181	
239	Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. 2018 , 13, 87-93	14
238	Management of newly diagnosed atrial fibrillation in an outpatient clinic setting-patient sett	11
237	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. 2018 , 121, 131-140	15
236	Preoperative Use of Oral Beta-Adrenergic Blocking Agents and the Incidence of New-Onset Atrial Fibrillation After Cardiac Surgery. A Systematic Review and Meta-Analysis. 2018 , 27, 310-321	15
235	Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. 2018 , 155, 1536-1542.e2	22
234	3D patient-specific models for left atrium characterization to support ablation in atrial fibrillation patients. 2018 , 45, 51-57	7
233	Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China. 2018 , 34, 255-261	10
232	Digoxin Is Associated With Increased Shock Events and Electrical Storms in Patients With Implantable Cardioverter Defibrillators. 2018 , 23, 142-148	6
231	Prevention of Stroke in Atrial Fibrillation. 2018 , 1092-1100	
230	Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants. 2018 , 34, 285-295	7
229	Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. 2018 , 14, 89-99	

228	Detecting atrial fibrillation by deep convolutional neural networks. 2018 , 93, 84-92	152
227	Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. 2018 , 34, 487-498	27
226	Atrial Appendage Thrombosis Risk Is Lower for Atrial Flutter Compared with Atrial Fibrillation. 2018 , 131, 442.e13-442.e17	5
225	What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis. 2018 , 10, 1870	43
224	Thrombus Pharmacotherapy. 2018 , 587-603	1
223	Arrhythmias and conduction disorders associated with atrial septal defects. 2018 , 10, S2940-S2944	11
222	A Review of Triple Therapy in Acute Coronary Syndromes. 2018 , 6, 166-173	
221	Comedication with interacting drugs predisposes amiodarone users in cardiac and surgical intensive care units to acute liver injury: A retrospective analysis. 2018 , 97, e12301	3
220	Atrial Flutter: Diagnosis and Management strategies. 2018,	O
219	Screening for Atrial Fibrillation During Automatic Blood Pressure Measurements. 2018 , 6, 4400307	
219	Screening for Acrial Fibrillacion During Automatic blood Fressure Measurements. 2016, 0, 4400307	3
218	Anticoagulantes orales en pacientes con fibrilaciñ auricular no valvular y con bajo riesgo. 2018 , 150, 2-7	3
	Anticoagulantes orales en pacientes con fibrilacia auricular no valvular y con bajo riesgo. 2018 ,	3
218	Anticoagulantes orales en pacientes con fibrilacifi auricular no valvular y con bajo riesgo. 2018 , 150, 2-7	3
218	Anticoagulantes orales en pacientes con fibrilaciñ auricular no valvular y con bajo riesgo. 2018, 150, 2-7 Thrombosis in Atrial Fibrillation. 2018, 337-354 Impact of anticoagulation and platelet antiaggregation on anaemia and haemorrhagic events in	1
218 217 216	Anticoagulantes orales en pacientes con fibrilacifi auricular no valvular y con bajo riesgo. 2018, 150, 2-7 Thrombosis in Atrial Fibrillation. 2018, 337-354 Impact of anticoagulation and platelet antiaggregation on anaemia and haemorrhagic events in patients with chronic kidney disease stages 3 and 4. 2018, 151, 476-480 Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation. 2018,	
218 217 216 215	Anticoagulantes orales en pacientes con fibrilacifi auricular no valvular y con bajo riesgo. 2018, 150, 2-7 Thrombosis in Atrial Fibrillation. 2018, 337-354 Impact of anticoagulation and platelet antiaggregation on anaemia and haemorrhagic events in patients with chronic kidney disease stages 3 and 4. 2018, 151, 476-480 Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation. 2018, 88, 961 Underuse of Oral Anticoagulants in Patients With Ischemic Stroke and Atrial Fibrillation in China.	1
218 217 216 215	Anticoagulantes orales en pacientes con fibrilacifi auricular no valvular y con bajo riesgo. 2018, 150, 2-7 Thrombosis in Atrial Fibrillation. 2018, 337-354 Impact of anticoagulation and platelet antiaggregation on anaemia and haemorrhagic events in patients with chronic kidney disease stages 3 and 4. 2018, 151, 476-480 Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation. 2018, 88, 961 Underuse of Oral Anticoagulants in Patients With Ischemic Stroke and Atrial Fibrillation in China. 2018, 122, 2055-2061 High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation: Using Late Gadolinium	1 9

210	Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation: An Analysis Using Administrative Claims Data. 2018 , 35, 2069-2080		1	
209	Automatic Detection of Atrial Fibrillation Based on Continuous Wavelet Transform and 2D Convolutional Neural Networks. 2018 , 9, 1206		50	
208	Patient perspectives of participating in the cardiac CopenHeartRFA rehabilitation program for patients treated with ablation for atrial fibrillation. 2018 , 11, 167-174		10	
207	Safety of Edoxaban 30´mg in Elderly Patients with Severe Renal Impairment. 2018 , 38, 1023-1030		8	
206	Poor outcomes associated with antithrombotic undertreatment in patients with atrial fibrillation attending Gondar University Hospital: a retrospective cohort study. 2018 , 16, 22		6	
205	Interruption and Reversal of Direct Oral Anticoagulants in Preprocedural and Acute Settings. 2018 , 31, 817-827		1	
204	Ibrutinib-Associated Atrial Fibrillation. 2018 , 4, 1491-1500		70	
203	The Use of Intravenous Sotalol in Cardiac Arrhythmias. 2018 , 27, 1318-1326		7	
202	Smartwatches in the Fight Against Atrial Fibrillation: The Little Watch That Could. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2389-2391	15.1	3	
201	Comparing Management and Outcomes in Men and Women With Nonvalvular Atrial Fibrillation: Data From a Population-Based Cohort. 2018 , 4, 604-614		4	
200	Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry". 2018 , 264, 64-69		7	
199	Relevance of electrical connectivity between the coronary sinus and the left atrial appendage for the intentional electrical isolation of the left atrial appendage in treating persistent atrial fibrillation: Insights from the LEIO-AF study. 2018 , 4, 420-424		2	
198	Effects of atrial fibrillation on the arterial fluid dynamics: a modelling perspective. 2018 , 53, 3251-3267		8	
197	Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 17-26	15.1	34	
196	Cardiovascular Therapies Targeting Left Atrial Appendage. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 448-463	15.1	28	
195	Association between Sleep Apnea Hypopnea Syndrome and the Risk of Atrial Fibrillation: A Meta-Analysis of Cohort Study. 2018 , 2018, 5215868		13	
194	Applications of low-cost 3D printing in left atrial appendage closure using epicardial approaches initial clinical experience. 2018 , 15, 135-140		4	
193	Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation - A microsimulation study. <i>PLoS ONE</i> , 2018 , 13, e0199593	3.7	2	

192	The Beat Goes On: The Story of Five Ageless Cardiac Drugs. 2018 , 356, 441-450	5
191	NOAKs bei arteriellen Rekonstruktionen in der Geffhedizin. 2018 , 23, 76-81	
190	Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation. 2018 , 11, e006408	8
189	The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey. 2018 , 13, 1005-1007	О
188	Recent Trends in Oral Anticoagulant Use and Post-Discharge Complications Among Atrial Fibrillation Patients with Acute Myocardial Infarction. 2018 , 10, 1749	2
187	Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. 2018 , 46, 332-338	6
186	Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users. <i>PLoS ONE</i> , 2018 , 13, e0194099	14
185	Multi-ethnic genome-wide association study for atrial fibrillation. 2018 , 50, 1225-1233	277
184	Evaluation of new generation loop recorders placed during surgical ablation for atrial fibrillation. 2018 , 33, 416-419	1
183	Anticoagulant treatment of medical patients with complex clinical conditions. 2019 , 219, 34-43	
182	Application of net reclassification index to non-nested and point-based risk prediction models: a review. 2019 , 40, 1880-1887	15
181	Anticoagulant treatment of medical patients with complex clinical conditions. 2019 , 219, 34-43	
180	Atrial Fibrillation and Deterioration in Cognitive Function. 2019 , 44, 100386	3
179	Consensus Clinical Decision-Making Factors Driving Anticoagulation in Atrial Fibrillation. 2019 , 124, 1038-1043	2
178	Common Postcardiothoracic Surgery Arrhythmias. 2019 , 31, 367-388	2
177	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. 2019 , 76, 1192-1202	49
176	Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. 2019 , 83, 1538-1545	23
175	Left Atrial Appendage Electrical Isolation as a Target in Atrial Fibrillation. 2019 , 5, 407-416	13

174	Reply: Off-Label Use of Direct Oral Anticoagulants in Patients With Mitral Stenosis. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3362-3363	15.1	
173	When Is Syncope Arrhythmic?. 2019 , 103, 793-807		3
172	Gut Microbial Metabolite Trimethylamine N-Oxide Is Related to Thrombus Formation in Atrial Fibrillation Patients. 2019 , 358, 422-428		10
171	Risk of Mortality Following Catheter Ablation of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2254-2264	15.1	47
170	Atrial fibrillation care in rural communities: a mixed methods study of physician and patient perspectives. 2019 , 20, 144		5
169	Non-Pulmonary Vein Triggers of Atrial Fibrillation Are Likely to Arise from Low-Voltage Areas in the Left Atrium. 2019 , 9, 12271		16
168	A case of electrolyte disturbances leading to flecainide toxicity at normal serum levels and pacemaker malfunction. 2019 , 5, 448-451		4
167	Catheter Ablation of Long-standing Persistent Atrial Fibrillation: a Reckless Challenge or a Way to Real Cure?. 2019 , 49, 134-145		3
166	Unrepaired Primum Atrial Septal Defect With Atrial Fibrillation and Broad Complex Tachycardia. 2019 , 29-37		
165	Atrial Fibrillation in Heart Failure-Diagnostic, Therapeutic, and Prognostic Relevance. 2019 , 16, 108-115		0
164	Pediatric Cardiac Rehabilitation: a Review. 2019 , 7, 67-80		3
163	Predictive value of the induction test with atrial burst pacing with regard to long-term recurrence after ablation in persistent atrial fibrillation. 2019 , 35, 223-229		6
162	Is anticoagulant therapy always indicated in "medium-risk" patients with first diagnosed atrial fibrillation? Insights from a real world, 10-year observational study. 2019 , 288, 76-81		
161	Outcomes of Surgical Ablation in Patients With Atrial Fibrillation Undergoing Cardiac Surgeries. 2019 , 107, 1395-1400		2
160	Left atrial longitudinal strain by speckle tracking as independent predictor of recurrence after electrical cardioversion in persistent and long standing persistent non-valvular atrial fibrillation. 2019 , 35, 1587-1596		6
159	Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. 2019 , 42, 694-704		14
158	Evaluation of the Effect of Apixaban on INR in the Inpatient Population. 2019, 24, 355-358		4
157	Low-fluoroscopy atrial fibrillation ablation with contact force and ultrasound technologies: a learning curve. 2019 , 10, 1-7		3

156	Impact of pulmonary hypertension in patients undergoing atrial fibrillation ablation: A nationwide study. 2019 , 23, 100348	2
155	Atrial Fibrillation Ablation Should Be First-Line Therapy in Heart Failure Patients: CON. 2019 , 37, 197-206	
154	Advances in Atrial Fibrillation Ablation. 2019 , 252-288	
153	Randomized Clinical Trials of Catheter Ablation of Atrial Fibrillation in Congestive Heart Failure: Knowns and Unmet Needs. 2019 , 37, 167-176	1
152	Guideline-based Management of Patients With Atrial Fibrillation. 2019, 15, 54-59	0
151	Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. 2019 , 21, 3	
150	Prediction and Management of Recurrences after Catheter Ablation in Atrial Fibrillation and Heart Failure. 2019 , 37, 221-230	3
149	Reduced Dose Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation. 2019 , 8, 43-48	
148	Automatic Prediction of Atrial Fibrillation Based on Convolutional Neural Network Using a Short-term Normal Electrocardiogram Signal. 2019 , 34, e64	30
147	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. 2019 , 212, 113-119	45
146	Are we there yet with patent foramen ovale closure for secondary prevention in cryptogenic stroke? A systematic review and meta-analysis of randomized trials. 2019 , 7, 2050312119828261	0
145	Clinical service organisation for adults with atrial fibrillation. 2019,	Ο
144	Atrial Fibrillation in the Elderly: The Role of Sub-Clinical Isolated Cardiac Amyloidosis. 2019 , 9, 16584	8
143	Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in The Atherosclerosis Risk in Communities study. 2019 , 19, 262	1
142	Digital Medicine and Evolution of Remote Patient Monitoring in Cardiac Electrophysiology: A State-of-the-Art Perspective. 2019 , 21, 92	9
141	Geographic Disparities in the Incidence of Stroke among Patients with Atrial Fibrillation in the United States. 2019 , 28, 890-899	7
140	A new model to predict ischemic stroke in patients with atrial fibrillation using warfarin or direct oral anticoagulants. 2019 , 16, 820-826	3
139	CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis. 2019 , 42, 358-364	8

(2020-2019)

138	Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. 2019 , 280, 84-88	24
137	Catheter Ablation for Atrial Fibrillation. 2019 , 15, 19-25.e1	1
136	Supraventricular and Ventricular Arrhythmias in Acute Myocardial Infarction. 2019, 166-173.e3	
135	Warfarin use increases bleeding risk in hemodialysis patients with atrial fibrillation: A meta-analysis of cohort studies. 2019 , 34, 975-984	16
134	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. 2019, 73, e13285	7
133	Atrial flutter and embolic risk: The relationship between atrial flutter cycle length and left atrial appendage function. 2019 , 52, 11-16	1
132	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. 2019 , 74, 309-318	11
131	Utilizing Native Directing Groups: Synthesis of a Selective I Inhibitor, BMS-919373, via a Regioselective C-H Arylation. 2019 , 84, 4704-4714	12
130	Periprocedural Management of Anticoagulation in Patients With Atrial Fibrillation. 2019, 105-119	
129	Persistent left superior vena cava as an arrhythmogenic source in atrial fibrillation: results from a multicenter experience. 2019 , 54, 93-100	7
128	Periprocedural Considerations for Anticoagulated Atrial Fibrillation Patients. 2019, 34, 227-239	О
127	Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin. 2019 , 19, 203-212	1
126	Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. 2019 , 25, 52-59	10
125	Analyzing electrocardiogram signals obtained from a nymi band to detect atrial fibrillation. 2020 , 79, 15985-15999	1
124	The effect of esophageal cooling on esophageal injury during radiofrequency catheter ablation of atrial fibrillation. 2020 , 58, 43-50	9
123	Epidemiology of early repolarization pattern in an adult general population. 2020 , 75, 713-723	4
122	Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. 2020 , 132, 97-109	4
121	Pulmonary Delivery of Metoprolol Reduces Ventricular Rate During Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm. 2020 , 75, 135-140	1

120	Postoperative Atrial Fibrillation and Long-Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery. 2020 , 142, 1320-1329	15
119	Comparison of Outcomes After Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. 2020 , 136, 62-70	3
118	National Physician Survey for Nonvalvular Atrial Fibrillation (NVAF) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs. 2020 , 26, 1076029620952550	1
117	Evaluation of the blood pressure effects of diltiazem versus metoprolol in the acute treatment of atrial fibrillation with rapid ventricular rate. 2021 , 46, 329-334	O
116	Impact of comorbid conditions on disease-specific quality of life in older men and women with atrial fibrillation. 2020 , 29, 3285-3296	3
115	Anticoagulation in Patients with Aortic Stenosis and Atrial Fibrillation. 2020 , 4, 360-368	1
114	Comorbidity burden in patients undergoing left atrial appendage closure. 2020,	1
113	External versus internal cardioversion for atrial fibrillation: a meta-analysis of randomized controlled trials. 2021 , 61, 445-451	
112	The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study. 2020 , 52, 529-538	3
111	Radiofrequency atrial fibrillation ablation with irrigated tip catheter using remote magnetic navigation compared with conventional manual method. 2021 , 62, 95-102	2
110	World Caf`approach: exploring the future vision of oral anticoagulants for patients with atrial fibrillation (AF) in Ireland. 2020 , 10, e036493	
109	Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation. 2021 , 14, 492-502	3
108	Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation. 2020 , 20, 343	3
107	Appropriate use of anti-thrombotic therapy in patients with atrial fibrillation at single-center experience, Northwest Ethiopia. 2020 , 20, 375	3
106	Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. 2020 , 7, e001257	10
105	The Symptom Experience of Patients With Atrial Fibrillation Before Their Initial Diagnosis. 2020 , 35, 347-357	4
104	Utilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort. 2020 , 71, e604-e613	5
103	Master Endurance Athletes and Cardiovascular Controversies. 2020 , 19, 113-118	7

102	Insights into hospital readmission patterns of atrial fibrillation patients. 2020 , 19, 545-550	2
101	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1145-1155	1 19
100	Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. 2020 , 8,	2
99	CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation. 2020 , 21, 200-208	1
98	Masa auricular derecha: la importancia del ecocardiograma al momento del diagn\(\beta\)tico de fibrilaci\(\beta\) auricular en el enfoque terap\(\beta\)tico. 2020 , 27, 593-596	
97	Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience. 2020 , 320, 78-82	1
96	Initial Precipitants and Recurrence of Atrial Fibrillation. 2020, 13, e007716	18
95	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 2020 , 18, 85-101	1
94	The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: A systematic review and meta-analysis of observational studies. 2020 , 5, 155-168	3
93	Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients. 2020 , 29, 104718	8
92	Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial. 2021 , 7, f63-f71	10
91	Left Ventricular Electromechanical Remodeling Detected by Acoustic Cardiography in Paroxysmal Atrial Fibrillation. 2021 , 14, 348-354	1
90	Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. 2021 , 7, f3-f10	7
89	Recent Developments in Cardiology Procedures for Adult Congenital Heart Disease: The AnesthesiologistN Perspective. 2021 , 35, 741-751	3
88	Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. 2021, 24, 273-284	1
87	Direct oral anticoagulant use and outcomes in adult patients with Fontan circulation: A multicenter retrospective cohort study. 2021 , 327, 74-79	7
86	Thirty Controversies and Considerations in Hypertrophic Cardiomyopathy. 2021 , 5, 39-54	Ο
85	The symptom experience of early and late treatment seekers before an atrial fibrillation diagnosis. 2021 , 20, 231-242	4

84	Catheter ablation superiority over the pharmacological treatments in atrial fibrillation: a dedicated review. 2021 , 53, 551-557	2
83	Cardiovascular Complications. 2021 , 557-578	
82	Rate control with intravenous diltiazem, verapamil, and metoprolol in acute atrial fibrillation with rapid ventricular rate. 2021 , 9, 20503121211017756	0
81	Assessment of individual risk of food interactions while taking warfarin. <i>Terapevticheskii Arkhiv</i> , 0.9	1
80	Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review. 2021 , 897190021100	0212
79	Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. 2021 , 41, 341-351	4
78	Oral anticoagulation on patients with atrial fibrillation: are we doing a good job?. 2021, 53, S160-S161	
77	Commentary: What is the measure of success for atrial fibrillation ablation? Is a reduction in arrhythmia burden sufficient?. 2021 ,	
76	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. 2021, 14, 768-780	2
75	Non-invasive ablation of arrhythmias with stereotactic ablative radiotherapy. 2021 ,	3
74	Atrial fibrillation catheter ablation complications in obese and diabetic patients: Insights from the US Nationwide Inpatient Sample 2005-2013. 2021 , 44, 1151-1160	1
73	Cardioversion of Atrial Fibrillation with Acupuncture. 2021 , 33, 235-239	
72	Mitral Annular Dynamics in AF Versus Sinus Rhythm: Novel Insights Into the Mechanism of AFMR. 2021 ,	1
71	Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver. 2021 , 10600280211032293	
70	The Role of Exosomes and Their Cargos in the Mechanism, Diagnosis, and Treatment of Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 712828	1
69	Risk Factors and Prevention. 2022 , 187-206.e6	
68	Comparison of Clonidine and Metoprolol Effectiveness on the Control of Post-Operative Blood Pressure in Otorhinolaryngology-Head and Neck Surgeries: A Clinical Trial. 2021 , 11, 49-58	
67	Positive Inotropic Drugs for Treating Heart Failure. 2021 ,	

66	Conventional Surgery for LAA Closure. <i>Contemporary Cardiology</i> , 2016 , 61-80	0.1	1
65	Segmenting Atrial Fibrosis from Late Gadolinium-Enhanced Cardiac MRI by Deep-Learned Features with Stacked Sparse Auto-Encoders. 2017 , 195-206		7
64	Avoiding non-responders to cardiac resynchronization therapy: a practical guide. 2017 , 38, 1463-1472		117
63	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. 2016 , 5, 2887		3
62	Assessment of Direct Oral Anticoagulant Prescribing and Monitoring Pre- and Post-Implementation of a Pharmacy Protocol at a Community Teaching Hospital. 2017 , 52, 207-213		6
61	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. <i>PLoS ONE</i> , 2017 , 12, e0189495	3.7	58
60	Drug Therapy Problems and the Role of Clinical Pharmacist in Surgery Ward: Prospective Observational and Interventional Study. 2020 , 12, 71-83		10
59	Stroke prevention in nonvalvular atrial fibrillation: update on target-specific oral anticoagulants. 2015 , 46, 152-4		2
58	Beta-Adrenergic Blockade in Critical Illness. 2021 , 12, 735841		4
57	Predicting Long-term Maintenance of Sinus Rhythm after Cardioversion in Patients with Nonvalvular Persistent Atrial Fibrillation. 2014 , 4, 8-13		
56	New Role of Biomarkers in Atrial Fibrillation. 2015 , 1-33		
55	Cardiac Hypertrophy and Hypertrophic Cardiomyopathy: Introduction and Management. 2015 , 291-324		
54	Thromboprophylaxis in Patients with Atrial Fibrillation: A Real Practice Analysis. 2016 , 3, GRHTA.50002	03a	
53	Discharge Planning. Contemporary Cardiology, 2016 , 187-194	0.1	O
52	Anticoagulation in Cardiovascular Diseases. 2016 , 195-214		
51	Elements of the Echocardiographic Exam. 2016 , 299-308		
50	PERIOPERATIVE MANAGEMENT OF PATIENTS WITH TACHYARRHYTHMIAS IN NON-CARDIAC SURGERY. <i>Alexander Saltanov Intensive Care Herald</i> , 2017 , 37-55	0.8	4
49	Best Practice for Switching Stable Warfarin Patients. 2017 , 93-99		

48	Translation and Validation of the Taiwanese Version of the Self-Efficacy for Appropriate Medication Use Scale. <i>Open Journal of Nursing</i> , 2017 , 07, 28-38	0.3	О
47	Oral Anticoagulants in Patients with Variable Renal Function. 2017, 61-68		
46	Frailty and Heart Disease. 2017 , 41-58		
45	ECG I. 2017 , 89-94		
44	PERIOPERATIVE MANAGEMENT OF PATIENTS WITH BRADYARRHYTHMIAS UNDERGOING NONCARDIAC SURGERY. <i>Alexander Saltanov Intensive Care Herald</i> , 2017 , 5-18	0.8	1
43	ANALYSIS OF ANTICOAGULATION THERAPY IN ATRIAL FIBRILLATION IN OUTPATIENT PRACTICE. 2018 , 66, 28-31		
42	Predicting team-performance and leadership in emergency situations by observing standardised operational procedures: a prospective single-blind simulator-based trial <i>BMJ Simulation and Technology Enhanced Learning</i> , 2019 , 5, 102-107	1.1	
41	Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation. <i>European Journal of Arrhythmia & Electrophysiology</i> , 2019 , 5, 24	0.3	
40	Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. 2019 , 736-740.e2		
39	Riesgo emblico, riesgo isquímico y riesgo hemorrgico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019 , 18, 3-8	0.2	
38	Fall 13 âDie Hemikolektomie. 2019 , 177-197		
37	Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in the Atherosclerosis Risk in Communities Study.		
36	[Thrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary intervention]. <i>Terapevticheskii Arkhiv</i> , 2019 , 91, 38-46	0.9	2
35	Ventricular Tachycardia and Fibrillation: Pharmacologic Therapy. Contemporary Cardiology, 2020 , 421-4	13 6 .1	
34	Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
33	Review of Deep Learning-Based Atrial Fibrillation Detection Studies. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	9
32	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021 , 20, 103-107	1.3	0
31	Demonstration of the potential of white-box machine learning approaches to gain insights from cardiovascular disease electrocardiograms. <i>PLoS ONE</i> , 2020 , 15, e0243615	3.7	3

30	Left atrial shape is independent predictor of arrhythmia recurrence after catheter ablation for atrial fibrillation: A shape statistics study <i>Heart Rhythm O2</i> , 2021 , 2, 622-632	1.5	O
29	Postoperative atrial fibrillation as a risk factor for cardiovascular complications in non-cardiac surgery. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020 , 19, 2540	0.9	1
28	Arrythmias in Chronic Kidney Disease: Working Towards a Clinical Approach in Atrial Fibrillation. 2021 , 47-57		
27	Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection. <i>International Journal of Cardiovascular Sciences</i> , 2020 ,	0.4	
26	Risk factor management of atrial fibrillation using mHealth: The Atrial Fibrillation - Helping Address Care with Remote Technology (AF-HEART) Pilot Study <i>Cardiovascular Digital Health Journal</i> , 2022 , 3, 14-20	2	
25	Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation: A Report From the National Heart, Lung, and Blood Institute and the National Institutes of Health Office of the Director Workshop <i>JACC Basic To Translational Science</i> , 2022 , 7, 265-293	8.7	2
24	Atrial Fibrillation. 2022, 294-318		
23	Location and coupling interval of an ectopic excitation determine the initiation of atrial fibrillation from the pulmonary veins <i>Journal of Cardiovascular Electrophysiology</i> , 2022 ,	2.7	
22	Ischemic Stroke in Non-Gender-Related CHADS-VA Score 0~1 Is Associated With HFPEF Score Among the Patients With Atrial Fibrillation <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 791112	5.4	O
21	Polysomnography in AF patients without prior diagnosis of obstructive sleep apnea reveals significant sleep abnormality: A strong case for screening in all patients with atrial fibrillation?. <i>Indian Pacing and Electrophysiology Journal</i> , 2022 ,	1.5	
20	Risk of Death and Ischemic Stroke in Patients with Atrial Arrhythmia and Thrombus or Sludge in Left Atrial Appendage at One-Year Follow-Up <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
19	Amplatzer AmuletâlLeft Atrial Appendage Occluder: A Step-By-Step Guide to Device Implantation Journal of Cardiovascular Electrophysiology, 2022,	2.7	O
18	Predicting atrial fibrillation episodes with rapid ventricular rates associated with low levels of activity <i>BMC Medical Informatics and Decision Making</i> , 2021 , 21, 364	3.6	1
17	The Comprehensive Diagnostic Transesophageal Echocardiogram. 2017 , 37-58		
16	Short-Term Natural Course of Esophageal Thermal Injury After Ablation for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> ,	2.7	
15	Comparative Risks of Fracture Among Direct Oral Anticoagulants and Warfarin: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9,	5.4	
14	Mid-Life Cardiorespiratory Fitness, Obesity, and Risk of Atrial Fibrillation: The Cooper Center Longitudinal Study. 2022 , 1, 100040		1
13	Clinical profile and side effects of chronic use of oral amiodarone in cardiology outpatients department (Clipse-A study)- A prospective observational study. <i>Annals of Medicine and Surgery</i> , 2022 , 104167	2	O

Cost-utility analysis of Cryoballoon ablation versus Radiofrequency ablation in the treatment of paroxysmal atrial fibrillation in Iran. **2022**, 17, e0270642

11	Stroke risk evaluation for patients with atrial fibrillation: Insights from left atrial appendage. 9,	
10	Composite Index Tagging for PVI în Paroxysmal AF. 2022 , 8, 1077-1089	3
9	Cardiac biomarkers and detection methods for myocardial infarction. 2022 , 18, 443-455	O
8	Left Atrial Appendage Dimension Predicts Elevated Brain Natriuretic Peptide in Non-Valvular Atrial Fibrillation.	O
7	Impact of redo ablation for atrial fibrillation on patient-reported outcomes and quality of life.	O
6	Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding. 2022 , 0	O
5	Comparison of effectiveness and safety of high-power vs. conventional-power radiofrequency ablation for treatment of atrial fibrillation. 9,	O
4	Pill in the Pocket. 2022 , 8, 1521-1522	O
3	Microprotein Dysregulation in the Serum of Patients with Atrial Fibrillation. 2023 , 22, 1172-1180	O
2	Impact of LGE-MRI in Arrhythmia Ablation. 2023 , 13, 3862	O
1	Detection of atrial fibrillation based on Stockwell transformation using convolutional neural networks.	O